Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous

Liding Zhao1,2, Tian Xu1,2, Ya Li1,2

  • 1Department of Cardiovascular Diseases, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, No 3 East of Qinchun Road, Hangzhou, Zhejiang, 310000, People's Republic of China.

Insights

Blood lipid variability, specifically in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), significantly impacts neutrophil-to-lymphocyte ratio (NLR) values and their variability. These lipid variations are identified as key risk factors for inflammation markers in patients.

Area of Science:

  • Cardiovascular Research
  • Inflammation Biomarkers
  • Lipid Metabolism

Background:

  • Atherosclerosis is linked to chronic inflammation and altered lipid metabolism.
  • The neutrophil-to-lymphocyte ratio (NLR) indicates inflammation and predicts cardiovascular disease prognosis.
  • The impact of blood lipid variability on NLR remains underexplored.

Purpose of the Study:

  • To investigate the relationship between blood lipid variability and NLR.
  • To determine if lipid variability influences inflammation markers like NLR.

Main Methods:

  • Univariate and multivariate linear regression analyses were employed.
  • Subgroup analyses were conducted to validate findings across different patient groups.

Main Results:

  • Variability in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were significant risk factors for NLR values.
  • Lipid variability, not baseline levels, predicted NLR values and variability.
  • HDL-C variability showed a more consistent association with NLR across subgroups compared to LDL-C variability.

Conclusions:

  • Variability in HDL-C and LDL-C are risk factors for NLR values and variability.
  • HDL-C variability demonstrates a more stable association with NLR than LDL-C variability.
  • Managing lipid variability may offer a novel strategy for controlling inflammation in patients, particularly those undergoing percutaneous coronary intervention (PCI).
Abstract